m+Medelevator.RU
← Поиск публикаций
Journal of human immunity · 2025

Intronic branchpoint-to-acceptor variants underlying inborn errors of immunity.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Alioua Najiba, Lambert Nathalie, Puel Mathilde, Hanein Sylvain, Bastard Paul, Fusaro Mathieu, Jaffray Marie, Medel Bernardita, Khellaf Lydia, Seeleuthner Yoann, Perin Mélodie, Jacques Corinne, Pasquet Marlène, Olivier Laura, Sepulveda Fernando, Le Voyer Tom, Cobat Aurélie, Nitschké Patrick, Galicier Lionel, Schleinitz Nicolas, Oksenhendler Eric, Malphettes Marion, Neven Bénédicte, Moshous Despina, Suarez Felipe, Fieschi Claire, Casanova Jean-Laurent, de Saint Basile Geneviève, Dorval Guillaume, Picard Capucine, Bustamante Jacinta, Zhang Peng, Rosain Jérémie

Аннотация

Clinical laboratories searching for pathogenic variants focus mostly on the protein-coding region and corresponding essential splicing sites. Screening for variants in intronic regions requires dedicated bioinformatics tools and detailed experimental studies to confirm deleteriousness and pathogenicity. We report intronic variants in a cohort of eight patients from seven kindreds with unexplained inborn errors of immunity (IEI). Using ad hoc bioinformatics tools, we identified seven kindreds carrying three branchpoint variants at three loci (BTK, SH2D1A, and WAS) and four AG-gain acceptor site variants at another three loci (DOCK8, NFKB1, STXBP2, and UNC13D). The variants were located between positions -9 and -49 relative to the wild-type acceptor site. The deleteriousness and, thus, pathogenicity of these variants were confirmed by exon-captured transcriptome studies and flow cytometry analyses of protein production or function. Our findings indicate that intronic variants should be systematically screened and investigated, even in clinical laboratory settings.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты